METHODS OF DETERMINING A PATIENT'S PROGNOSIS FOR RECURRENCE OF PROSTATE CANCER AND/OR DETERMINING A COURSE OF TREATMENT FOR PROSTATE CANCER FOLLOWING A RADICAL PROSTATECTOMY
First Claim
Patent Images
1. A method of determining a patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer, following a radical prostatectomy, comprising:
- performing an assay on a sample obtained from the patient following the radical prostatectomy to determine a measure of the concentration of prostate specific antigen (PSA) in the sample, wherein the concentration of PSA in the sample is less than about 50 pg/mL; and
determining the patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following the radical prostatectomy based at least in part on the measured concentration of PSA in the sample, wherein determining the patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment does not require measurement of a change in concentration of PSA measured in multiple patient samples as a function of time elapsed after the radical prostatectomy.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention generally relates, in some embodiments, to methods of determining a patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy.
-
Citations
33 Claims
-
1. A method of determining a patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer, following a radical prostatectomy, comprising:
-
performing an assay on a sample obtained from the patient following the radical prostatectomy to determine a measure of the concentration of prostate specific antigen (PSA) in the sample, wherein the concentration of PSA in the sample is less than about 50 pg/mL; and determining the patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following the radical prostatectomy based at least in part on the measured concentration of PSA in the sample, wherein determining the patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment does not require measurement of a change in concentration of PSA measured in multiple patient samples as a function of time elapsed after the radical prostatectomy. - View Dependent Claims (13, 14, 15, 16, 17, 19, 20, 28, 29, 30, 31, 32)
-
-
2-3. -3. (canceled)
-
4. A method of determining a patient'"'"'s prognosis for recurrence of prostate cancer, and/or determining a course of treatment for prostate cancer following a radical prostatectomy, comprising:
-
performing an assay on a sample obtained from the patient following the radical prostatectomy to determine a measure of the concentration of prostate specific antigen (PSA) in the sample, wherein the sample is obtained from the patient within 6 months following the radical prostatectomy; and determining the patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy based at least in part on the concentration of PSA measured in the sample, wherein determining the patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment does not require measurement of a change in concentration of PSA measured in multiple patient samples as a function of time elapsed after the radical prostatectomy. - View Dependent Claims (21, 22)
-
-
5-6. -6. (canceled)
-
7. A method of determining a patient'"'"'s prognosis for recurrence of prostate cancer, and/or determining a course of treatment for prostate cancer following a radical prostatectomy, comprising:
-
performing an assay on at least one sample obtained from the patient following the radical prostatectomy to determine a measure of the concentration of prostate specific antigen (PSA) in the at least one sample; and determining the patient'"'"'s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy based at least in part on the concentration of PSA measured in the at least one sample, wherein a measured concentration of PSA in the at least one sample greater than a threshold limit of no greater than about 10 pg/mL indicates a significant likelihood that the patient'"'"'s prostate cancer will reoccur within 5 years. - View Dependent Claims (23, 25, 26)
-
-
8-12. -12. (canceled)
-
18. (canceled)
-
24. (canceled)
-
27. (canceled)
-
33-49. -49. (canceled)
Specification